Switzerland, particularly the Basel-Zurich corridor, is a leading European biotechnology hub with a strong focus on neuroscience research and drug development. This page covers Swiss biotech companies developing treatments for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.
Switzerland's biotech ecosystem benefits from:
Basel is the heart of Swiss pharma and biotech, home to major companies and innovative startups.
Headquarters: Lausanne, Switzerland (operations in Basel region)
Ticker: NASDAQ: ACUI
Focus: Precision medicines for AD, PD, ALS
Platform: SupraAntigen™ and Morphomer™
Programs:
| Program | Target | Indication | Stage |
|---|---|---|---|
| Semorinemab | Tau | Alzheimer's Disease | Phase 2 |
| ACI-35.030 | Tau vaccine | Alzheimer's Disease | Phase 1b |
| ACI-24 | Amyloid-beta vaccine | Alzheimer's Disease | Phase 1 |
| ACI-40 | α-synuclein vaccine | Parkinson's Disease | Preclinical |
Partnerships: Genentech/Roche, Janssen
Website: acimmune.com
Asceneuron focuses on small molecule tau aggregation inhibitors that can penetrate the blood-brain barrier and target intracellular tau pathology.
Polyneuron is developing novel antibody therapeutics designed to selectively target misfolded proteins that accumulate in neurodegenerative diseases.
Zurich's biotech scene, anchored by ETH Zurich, produces innovative startups in the neurodegeneration space.
Headquarters: Allschwil, Switzerland
Ticker: SIX: IDIA
Focus: CNS disorders, including Alzheimer's and Parkinson's disease
Pipeline:
| Program | Target/Mechanism | Indication | Stage |
|---|---|---|---|
| Daridorexant | Orexin receptor antagonist | Insomnia (AD-related) | Approved |
| ACT-541468 | Sodium channel blocker | Pain/Epilepsy | Phase 2 |
| ACT-709478 | mGluR5 modulator | Parkinson's Disease | Phase 1 |
Partnerships: Janssen, Merck
Website: idorsia.com
Idorsia, spun out of Actelion in 2017, has a broad CNS pipeline targeting sleep disorders, pain, and neurodegenerative diseases.
Headquarters: Lausanne, Switzerland
Focus: Digital therapeutics and neuro rehabilitation
Technology: AI-powered neurorehabilitation platforms
Programs:
| Program | Description | Indication | Stage |
|---|---|---|---|
| MindMotion | Digital neurorehabilitation | Post-stroke, MS | Commercial |
| MindPod | VR-based motor rehabilitation | Neurological conditions | Clinical |
Partnerships: University Hospital of Lausanne, Cleveland Clinic
Website: mindmaze.com
MindMaze develops digital therapeutics combining virtual reality and AI for neurorehabilitation, addressing motor and cognitive recovery.
The Lake Geneva region (Lake Geneva Biocluster) is home to numerous biotech startups.
Headquarters: Schlieren, Switzerland
Focus: Antibody therapeutics for neurodegenerative diseases
Technology: Human antibody discovery platform
Programs:
| Program | Target | Indication | Stage |
|---|---|---|---|
| NI-202 | Amyloid-beta | Alzheimer's Disease | Preclinical |
| NI-301 | Tau | Alzheimer's Disease | Preclinical |
| NI-401 | α-synuclein | Parkinson's Disease | Preclinical |
Partnerships: Roche, Biogen
Website: neurimmune.com
Neurimmune uses its human antibody discovery platform to develop next-generation immunotherapies for neurodegenerative diseases.
| Institution | Location | Key Focus |
|---|---|---|
| ETH Zurich | Zurich | Neuroscience, AI, drug discovery |
| EPFL | Lausanne | Neuroengineering, brain mapping |
| University of Zurich | Zurich | Neurobiology, translational research |
| University of Basel | Basel | Pharmaceutical sciences |
| Friedrich Miescher Institute | Basel | Molecular neuroscience |
| Company | Location | Mechanism | Stage |
|---|---|---|---|
| AC Immune | Lausanne | Anti-tau mAb, vaccines | Phase 1-2 |
| Asceneuron | Lausanne | Tau aggregation inhibitor | Phase 1/2 |
| Neurimmune | Schlieren | Anti-Aβ antibodies | Preclinical |
| Idorsia | Allschwil | Various mechanisms | Research |
| Company | Location | Mechanism | Stage |
|---|---|---|---|
| AC Immune | Lausanne | α-syn vaccine | Preclinical |
| Idorsia | Allschwil | mGluR5 modulator | Phase 1 |
| Neurimmune | Schlieren | Anti-α-syn antibodies | Preclinical |
Swiss neurodegeneration biotech companies benefit from:
Swiss companies compete in the global neurodegeneration space against:
| Company | Location | Key Competitor |
|---|---|---|
| AC Immune | Switzerland | Eli Lilly, Biogen/Eisai |
| Asceneuron | Switzerland | TauRx, Axon Neuroscience |
| Neurimmune | Switzerland | Alector, Prothena |
| MindMaze | Switzerland | Pear Therapeutics, Akili Interactive |